Weekly Analysts’ Ratings Changes for Summit Therapeutics (SMMT)

A number of firms have modified their ratings and price targets on shares of Summit Therapeutics (NASDAQ: SMMT) recently:

• 8/12/2026 – Summit Therapeutics was upgraded by Leerink Partners from “underperform” to “market perform”. They now have a $13.00 price target on the stock, up from $12.00.
• 8/6/2026 – Summit Therapeutics had its “neutral” rating reaffirmed by HC Wainwright.
• 7/24/2026 – Summit Therapeutics was given a new $15.00 price target by Jefferies Financial Group Inc..
• 7/24/2026 – Summit Therapeutics had its price target lowered by Stifel Nicolaus from $45.00 to $38.00. They now have a “buy” rating on the stock.
• 7/24/2026 – Summit Therapeutics had its price target lowered by Guggenheim from $40.00 to $38.00. They now have a “buy” rating on the stock.
• 7/24/2026 – Summit Therapeutics had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 7/23/2026 – Summit Therapeutics had its “neutral” rating reaffirmed by HC Wainwright.
• 7/18/2026 – Summit Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 7/17/2026 – Summit Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/15/2026 – Summit Therapeutics had its “neutral” rating reaffirmed by HC Wainwright.
• 7/4/2026 – Summit Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.

Insiders Place Their Bets

In other Summit Therapeutics news, CEO Mahkam Zanganeh purchased 3,810,000 shares of Summit Therapeutics stock in a transaction dated Friday, June 12th. The stock was acquired at an average price of $13.12 per share, for a total transaction of $49,987,200.00. Following the acquisition, the chief executive officer owned 573,883,879 shares in the company, valued at $7,529,356,492.48. This trade represents a 0.67% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Robert W. Duggan purchased 3,810,000 shares of the stock in a transaction dated Friday, June 12th. The stock was acquired at an average cost of $13.12 per share, with a total value of $49,987,200.00. Following the transaction, the chief executive officer directly owned 573,883,879 shares in the company, valued at approximately $7,529,356,492.48. This trade represents a 0.67% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired a total of 7,870,000 shares of company stock worth $103,616,900 in the last three months. Corporate insiders own 83.50% of the company’s stock.

Summit Therapeutics plc is a clinical‐stage biotechnology company dedicated to the discovery and development of precision medicines for serious and life‐threatening diseases. The company applies a targeted approach to drug design, focusing on novel mechanisms of action that differentiate its candidates from existing therapies.

Summit’s lead asset, ridinilazole (formerly SMT19969), is being developed to treat Clostridioides difficile infections and has received both Fast Track and Qualified Infectious Disease Product designations from the U.S.